Glass was found in an injection medicine used for hospitalized COVID-19 patients
Two lots of Veklury, the brand name for remdisivir, have been recalled by Gilead Sciences after a company investigation confirmed a customer complaint about glass particulates in the injected medicine.
Though Gilead says in its FDA-posted recall notice that it hasn’t received any reports of “adverse events” yet, the potential problem is obvious:
“If the glass particulate reaches the blood vessels it can travel to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death.”
Lot Nos. 2141001-1A and 2141002-1A of 100mg Veklury, expiration “01/2024,” NDC No. 61958-2901-02 have been recalled. Hospitals with either of these lots should stop using them and return them as instructed by Gilead.
Anyone with questions can reach Gilead at 866-633-4474, Monday through Friday, 9 a.m. to 7 p.m., Eastern time or via the website.
If this or any other drug causes a medical problem, after notifying a medical professional, let the FDA know via its MedWatch Adverse Event page or by filling out a form you can get by calling 800-332-1088.
This story was originally published December 14, 2021 at 11:02 AM with the headline "Glass was found in an injection medicine used for hospitalized COVID-19 patients."
